• in-silico comparative studies of the effect of metformin and geraniol on gpc1 protein in endometrial cancer

    جزئیات بیشتر مقاله
    • تاریخ ارائه: 1401/03/31
    • تاریخ انتشار در تی پی بین: 1401/05/03
    • تعداد بازدید: 125
    • تعداد پرسش و پاسخ ها: 0
    • شماره تماس دبیرخانه رویداد: 09050265032

    in-silico comparative studies of the effect of metformin and geraniol on gpc1 protein in endometrial cancer

    endometrial cancer (ec) is the fourth most known carcinoma worldwide in females. geraniol (ger) is one of the acyclic monoterpene alcohols that got from essential oils of aromatic plants. metformin is the first-line medication that is recommended for patients with type 2 diabetes.

    newly, metformin has acquired an interest as an anti-cancer agent in a few carcinoma types, despite the fact that studies in ec are limited. glypican 1 (gpc1) is highly expressed in malignant tumors. the 3d structure of the targeted protein gpc1 (pdb id: 4ywt) was obtained from the pdb online database. in-silico molecular docking compounds analysis is performed in pyrx software with the autodock vina software.

    all compounds used in this study demonstrated significant anticancer activity against ec by binding to the inhibitor site of gpc1 protein. the result displayed the good potency as an inhibitor to gpc1with the optimum binding energy of -4, 5 kcal/mol in drug metformin and significantly -4, 9 kcal/ mol in geraniol compounds. these results predict that metformin and geraniol might have the potential as an anti-carcinoma against ec and could be developed to treat cancer.

سوال خود را در مورد این مقاله مطرح نمایید :

با انتخاب دکمه ثبت پرسش، موافقت خود را با قوانین انتشار محتوا در وبسایت تی پی بین اعلام می کنم
مقالات جدیدترین رویدادها